on CureVac (NASDAQ:CVAC)
CureVac Advances mRNA Immunotherapy for Lung Cancer
CureVac has received clearance from the U.S. FDA for its Investigational New Drug (IND) application, permitting the initiation of a Phase 1 clinical trial for its mRNA-based precision immunotherapy, CVHNLC, targeting squamous non-small cell lung cancer (sqNSCLC). This investigational therapy uses proprietary tumor epitopes and will be tested in combination with pembrolizumab to enhance targeted anti-tumor immune responses.
The upcoming phase 1 trial will explore CVHNLC's safety and tolerability, focusing on dose escalation in patients with advanced sqNSCLC. This milestone represents a significant advancement in CureVac's oncology pipeline, with patient treatments anticipated to commence in the latter half of 2025.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CureVac news